2026-04-29T04:09:11Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/184582024-09-27T12:12:23Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927
Repisalud
author
Cattrini, Carlo
author
España, Rodrigo
author
Mennitto, Alessia
author
Bersanelli, Melissa
author
Castro, Elena
author
Olmos, David
author
Lorente, David
author
Gennari, Alessandra
2024-02-19T15:30:57Z
2024-02-19T15:30:57Z
2021-09-08
2072-6694
http://hdl.handle.net/10668/18557
http://hdl.handle.net/20.500.12105/18458
34572748
10.3390/cancers13184522
Cancers
The treatment landscape of advanced prostate cancer has completely changed during the last decades. Chemotherapy (docetaxel, cabazitaxel), androgen-receptor signaling inhibitors (ARSi) (abiraterone acetate, enzalutamide), and radium-223 have revolutionized the management of metastatic castration-resistant prostate cancer (mCRPC). Lutetium-177-PSMA-617 is also going to become another treatment option for these patients. In addition, docetaxel, abiraterone acetate, apalutamide, enzalutamide, and radiotherapy to primary tumor have demonstrated the ability to significantly prolong the survival of patients with metastatic hormone-sensitive prostate cancer (mHSPC). Finally, apalutamide, enzalutamide, and darolutamide have recently provided impactful data in patients with nonmetastatic castration-resistant disease (nmCRPC). However, which is the best treatment sequence for patients with advanced prostate cancer? This comprehensive review aims at discussing the available literature data to identify the optimal sequencing approaches in patients with prostate cancer at different disease stages. Our work also highlights the potential impact of predictive biomarkers in treatment sequencing and exploring the role of specific agents (i.e., olaparib, rucaparib, talazoparib, niraparib, and ipatasertib) in biomarker-selected populations of patients with prostate cancer (i.e., those harboring alterations in DNA damage and response genes or PTEN).
eng
LuPSMA
PARP inhibitors
androgen-receptor signaling inhibitors
chemotherapy
ipatasertib
metastatic castration-resistant prostate cancer
metastatic hormone-naïve prostate cancer
metastatic hormone-sensitive prostate cancer
nonmetastatic castration-resistant prostate cancer
Optimal Sequencing and Predictive Biomarkers in Patients with Advanced Prostate Cancer.
research article